AXNX News and Press, Axonics Modulation Technologies Inc. From 03/02/21

Axonics Modulation Technologies (AXNX) has entered into a strategic alliance with Micro Systems Technologies ((MST)). This strategic alliance expands Axonics’ relationship with MST, with the parties collaborating on the non-rechargeable implantable sacral neuromodulation ((SNM)) d...

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it has entered into a strategic alliance with Micro Systems Technologies...

The following slide deck was published by Axonics Modulation Technologies, Inc. in conjunction with this event. For further details see: Axonics Modulation Technologies (AXNX) Overview of Bulkamid - Slideshow

Axonics Modulation Technologies, Inc. (AXNX) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Neil Bhalodkar – Vice President of Investor Relations Raymond Cohen – Chief Executive Officer Dan Dearen – President and Chief Financial Officer...

Axonics Modulation Technologies (AXNX): Q4 GAAP EPS of -$0.29.Revenue of $34.8M (+249.7% Y/Y)Press Release For further details see: Axonics Modulation Technologies reports Q4 results

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fisca...

Combination creates a global leader for incontinence solutions Acquisition of Bulkamid is expected to be immediately accretive to Axonics Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializ...

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financi...

Two-year Results from ARTISAN-SNM Study to be Presented at Plenary Session Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatmen...

Axonics Modulation Technologies (AXNX) receives PMA supplement approval from the FDA for its third-generation implantable neurostimulator ((INS)). The third-generation INS upgrades the embedded software in the INS and the functionality of the patient remote control. Shipment of the third-gene...